ArticleTranslational lung cancer research2022

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.

Yizhuo Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.